DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Betadex is an investigational drug.
There have been 11 clinical trials for Betadex. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Niemann-Pick Diseases, Niemann-Pick Disease, Type C, and Niemann-Pick Disease, Type A. The leading clinical trial sponsors are Bayer, Mandos LLC, and Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company.
There are five hundred and eighty-two US patents protecting this investigational drug and twelve international patents.
Recent Clinical Trials for Betadex
|Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440||Janssen Research & Development, LLC||Phase 1|
|Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System||Mandos LLC||Phase 3|
|Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System||Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company||Phase 3|
Top disease conditions for Betadex
Top clinical trial sponsors for Betadex
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Betadex||⤷ Try it Free||Antifungal compound process||Mycovia Pharmaceuticals, Inc. (Durham, NC) U.S. Department of Health and Human Services (Washington, DC)||⤷ Try it Free|
|Betadex||⤷ Try it Free||Pharmaceutical composition for preventing or treating skin cancer comprising Panax spp. plant extract and method of preventing or treating skin cancer in a subject using the same||KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (Seoul, KR)||⤷ Try it Free|
|Betadex||⤷ Try it Free||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||⤷ Try it Free|
|Betadex||⤷ Try it Free||Neprilysin inhibitors||THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)||⤷ Try it Free|
|Betadex||⤷ Try it Free||Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer||Capella Therapeutics, Inc. (San Diego, CA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Betadex||Australia||AU2015231234||2034-03-19||⤷ Try it Free|
|Betadex||Canada||CA2942972||2034-03-19||⤷ Try it Free|
|Betadex||European Patent Office||EP3119755||2034-03-19||⤷ Try it Free|
|Betadex||Japan||JP2017509646||2034-03-19||⤷ Try it Free|
|Betadex||World Intellectual Property Organization (WIPO)||WO2015143180||2034-03-19||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|